Statement by Michael A. Carrier to House Energy & Commerce Committee (Subcommittee on Consumer Protection and Commerce)

House Subcommittee of House Energy & Commerce Committee hearing September 19, 2019

3 Pages Posted: 22 Oct 2019

Date Written: September 19, 2019

Abstract

Drug companies have engaged in "product hopping," reformulating a drug so a generic can't be substituted while encouraging doctors to prescribe the new version. My statement (1) defines the activity, (2) reveals harms suffered by consumers, (3) offers concerning examples, (4) shows how product hopping harms innovation, and (5) provides solutions.

Keywords: antitrust, pharmaceuticals, drugs, product hopping

JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38

Suggested Citation

Carrier, Michael A., Statement by Michael A. Carrier to House Energy & Commerce Committee (Subcommittee on Consumer Protection and Commerce) (September 19, 2019). House Subcommittee of House Energy & Commerce Committee hearing September 19, 2019 , Available at SSRN: https://ssrn.com/abstract=3464850

Michael A. Carrier (Contact Author)

Rutgers Law School ( email )

217 North Fifth Street
Camden, NJ 08102-1203
United States
856-225-6380 (Phone)
856-225-6516 (Fax)

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
7
Abstract Views
128
PlumX Metrics